$2.25T
Total marketcap
$119.52B
Total volume
BTC 50.39%     ETH 15.66%
Dominance

Bukwang Pharmaceutical Co., Ltd. 003000.KS Stock

5950 KRW {{ price }} -1.976936% {{change_pct}}%
Exchange
KSE
Market Cap
407.31B KRW
LOW - HIGH [24H]
5860 - 5990 KRW
VOLUME [24H]
69.07K KRW
{{ volume }}
P/E Ratio
0
Earnings per share
0 KRW

Bukwang Pharmaceutical Co., Ltd. Price Chart

Bukwang Pharmaceutical Co., Ltd. 003000.KS Financial and Trading Overview

Bukwang Pharmaceutical Co., Ltd. stock price 5950 KRW
Previous Close 7200 KRW
Open 7160 KRW
Bid 7250 KRW x 0
Ask 7260 KRW x 0
Day's Range 7160 - 7290 KRW
52 Week Range 6800 - 10800 KRW
Volume 109.67K KRW
Avg. Volume 112.71K KRW
Market Cap 496.98B KRW
Beta (5Y Monthly) -0.060286
PE Ratio (TTM) N/A
EPS (TTM) 0 KRW
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date December 29, 2021
1y Target Est N/A

003000.KS Valuation Measures

Enterprise Value 389.65B KRW
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.5988655
Price/Book (mrq) N/A
Enterprise Value/Revenue 2.038
Enterprise Value/EBITDA 182.215

Trading Information

Bukwang Pharmaceutical Co., Ltd. Stock Price History

Beta (5Y Monthly) -0.060286
52-Week Change -16.57%
S&P500 52-Week Change 20.43%
52 Week High 10800 KRW
52 Week Low 6800 KRW
50-Day Moving Average 7945 KRW
200-Day Moving Average 8236.35 KRW

003000.KS Share Statistics

Avg. Volume (3 month) 112.71K KRW
Avg. Daily Volume (10-Days) 117.85K KRW
Shares Outstanding 68.45M
Float 40.54M
Short Ratio N/A
% Held by Insiders 30.24%
% Held by Institutions 8.08%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate N/A
Trailing Annual Dividend Yield N/A
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1.1:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -2.75%
Operating Margin (ttm) -1.53%
Gross Margin 42.00%
EBITDA Margin 1.11%

Management Effectiveness

Return on Assets (ttm) -0.47%
Return on Equity (ttm) -2.70%

Income Statement

Revenue (ttm) 191.23B KRW
Revenue Per Share (ttm) 2746.15 KRW
Quarterly Revenue Growth (yoy) 0.89%
Gross Profit (ttm) N/A
EBITDA 2.14B KRW
Net Income Avi to Common (ttm) -5259222528 KRW
Diluted EPS (ttm) N/A
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 69.8B KRW
Total Cash Per Share (mrq) 1181.1 KRW
Total Debt (mrq) 988.53M KRW
Total Debt/Equity (mrq) 0.37 KRW
Current Ratio (mrq) 6.243
Book Value Per Share (mrq) N/A

Cash Flow Statement

Operating Cash Flow (ttm) -16311250944 KRW
Levered Free Cash Flow (ttm) -5113888256 KRW

Profile of Bukwang Pharmaceutical Co., Ltd.

Country South Korea
State N/A
City Seoul
Address 7, Sangdo-ro
ZIP 06955
Phone 82 2 828 8114
Website https://www.bukwang.co.kr
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees N/A

Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.

Q&A For Bukwang Pharmaceutical Co., Ltd. Stock

What is a current 003000.KS stock price?

Bukwang Pharmaceutical Co., Ltd. 003000.KS stock price today per share is 5950 KRW.

How to purchase Bukwang Pharmaceutical Co., Ltd. stock?

You can buy 003000.KS shares on the KSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Bukwang Pharmaceutical Co., Ltd.?

The stock symbol or ticker of Bukwang Pharmaceutical Co., Ltd. is 003000.KS.

Which industry does the Bukwang Pharmaceutical Co., Ltd. company belong to?

The Bukwang Pharmaceutical Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.

How many shares does Bukwang Pharmaceutical Co., Ltd. have in circulation?

The max supply of Bukwang Pharmaceutical Co., Ltd. shares is 68.45M.

What is Bukwang Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?

Bukwang Pharmaceutical Co., Ltd. PE Ratio is now.

What was Bukwang Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?

Bukwang Pharmaceutical Co., Ltd. EPS is 0 KRW over the trailing 12 months.

Which sector does the Bukwang Pharmaceutical Co., Ltd. company belong to?

The Bukwang Pharmaceutical Co., Ltd. sector is Healthcare.